[Form 4] Idexx Laboratories Inc Insider Trading Activity

Rhea-AI Filing Summary

Nimrata Hunt, Executive Vice President of IDEXX Laboratories, reported transactions in the issuer's common stock (ticker IDXX). The filing shows a sale and subsequent option exercises that largely offset each other. On 08/11/2025 she sold 1,200 shares at $656.5335, leaving 16,806.9435 shares held directly. On 08/12/2025 she acquired shares through the exercise of previously granted options: 560 at $178.26, 483 at $206.94, and 183 at $544.08, bringing direct beneficial ownership to 18,032.9435 shares. The filing also notes 160 shares held indirectly, jointly with a spouse. The exercised options correspond to grants that became exercisable in one installment on Feb 14, 2023, Feb 14, 2024, and Feb 14, 2025.

Positive

• Exercises of long-standing option grants (became exercisable in 2023, 2024 and 2025) indicate alignment with equity compensation schedules
• Net direct holdings increased to 18,032.9435 shares after reported transactions

Negative

• Sale of 1,200 shares on 08/11/2025 by an executive could be viewed by some investors as a liquidity event
• 160 shares held indirectly jointly with spouse adds a layer of indirect ownership that investors may note for governance context

Insights

Financial Analyst

TL;DR: Routine option exercises and a small sale by an executive; net share holdings increased modestly.

The filing documents a sale of 1,200 shares followed by the exercise of 1,226 option-based rights, resulting in a net increase of 26 shares in direct beneficial ownership to 18,032.9435 shares. The exercises were of incentive stock options with stated exercise prices of $178.26, $206.94 and $544.08. These appear to be exercises of previously granted awards that became exercisable in annual installments, which is common compensation behavior and not, on its face, a material change to ownership for a large-cap issuer.

Corporate Governance Expert

TL;DR: Transactions align with equity-based compensation schedules; sale likely routine rather than signaling governance concerns.

The report shows exercises tied to option grants that became exercisable in specified prior years and a contemporaneous sale of 1,200 shares. The filing notes 160 shares held indirectly with a spouse. From a governance perspective, these disclosures illustrate standard executive participation in equity programs and transparent reporting under Section 16. There is no explicit indication of unusual timing or related-party transaction beyond the spouse-held shares disclosed as indirect ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hunt Nimrata

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		S		1,200	D	$656.5335	16,806.9435	D
Common Stock	08/12/2025		M		560	A	$178.26	17,366.9435	D
Common Stock	08/12/2025		M		483	A	$206.94	17,849.9435	D
Common Stock	08/12/2025		M		183	A	$544.08	18,032.9435	D
Common Stock								160	I	jointly with spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right-to-buy)	$178.26	08/12/2025		M			560	(1)	02/13/2028	Common Stock	560	$0	0	D
Incentive Stock Option (right-to-buy)	$206.94	08/12/2025		M			483	(2)	02/13/2029	Common Stock	483	$0	0	D
Incentive Stock Option (right-to-buy)	$544.08	08/12/2025		M			183	(3)	02/13/2031	Common Stock	183	$0	0	D

Explanation of Responses:

1. Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2023.

2. Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2024.

3. Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did IDEXX (IDXX) report on this Form 4?

The report shows Executive Vice President Nimrata Hunt sold 1,200 shares on 08/11/2025 and exercised options for 560, 483 and 183 shares on 08/12/2025.

How many shares did Nimrata Hunt own after these transactions?

Following the reported transactions, the filing lists 18,032.9435 shares held directly and 160 shares held indirectly (jointly with spouse).

What were the exercise prices for the options exercised?

The derivative table shows exercise prices of $178.26, $206.94, and $544.08 for the respective option exercises.

Were the exercised options from recent grants or older awards?

The filing explains the options were grants that became exercisable in one installment on Feb 14, 2023, Feb 14, 2024, and Feb 14, 2025.

Does the Form 4 indicate joint ownership or indirect holdings?

Yes, the filing discloses 160 shares held indirectly and reported as jointly owned with a spouse.